Clinical Trials Logo

Relapsed Acute Myeloid Leukemia clinical trials

View clinical trials related to Relapsed Acute Myeloid Leukemia.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT04797767 Suspended - Clinical trials for Acute Myeloid Leukemia

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Start date: February 4, 2022
Phase: Phase 1
Study type: Interventional

This phase I trial finds the best dose and side effects of venetoclax in combination with cladribine, cytarabine, granulocyte colony-stimulating factor, and mitoxantrone (CLAG-M) in treating patients with acute myeloid leukemia and high-grade myeloid neoplasms. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as cladribine, cytarabine, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax with CLAG-M may kill more cancer cells.